DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity. DIANA is straightforward to develop for new targets and easy to implement using standard laboratory equipment.

DIANA Kinase Panel, which currently enables rapid potency and selectivity profiling of target compounds against approximately 150 kinases, representing clinically relevant kinases from all kinase families (AGC, CAMK, CK1, CMGC, STE, TK, TKL).

The gradual panel expansion is introducing the complete subsets corresponding to specific kinase families. As an example, the first complete DIANA CDK Panel is available for small molecules profiling

• ​Quantitative PCR-based readout → Ki from a single well.

• Low consumption of reagents → cost-effective.​

• 384-well plate format → high-throughput.​

• Rapid inhibitor selectivity profiling against CDKs.​

• Any CDK included in the DIANA CDK inhibitor profiling panel can be used in HTS campaigns (Z’ > 0.7) using our in-house compound libraries.